Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting

Basit Öğe Kaydı
dc.authorid0000-0001-5673-8408en_US
dc.contributor.authorEskazan, Ahmet Emre
dc.contributor.authorAli, Rıdvan
dc.contributor.authorAlnıgeniş, Ebru
dc.contributor.authorAyyıldız, Orhan
dc.contributor.authorHaznedaroğlu, İbrahim
dc.contributor.authorKırkızlar, Onur
dc.contributor.authorKurtoğlu, Erdal
dc.contributor.authorMalhan, Simten
dc.contributor.authorÖksüz, Ergün
dc.contributor.authorPolat, Özlem
dc.contributor.authorSaydam, Güray
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorToprak, Selami Koçak
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorTurgut, Mehmet
dc.date.accessioned2022-04-11T12:58:35Z
dc.date.available2022-04-11T12:58:35Z
dc.date.issued2022en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıklar Ana Bilim Dalı, Hematoloji Bilim Dalıen_US
dc.descriptionWOS:000764920100001
dc.descriptionPMID: 35184657
dc.description.abstractIntroduction The therapeutic landscape of chronic myeloid leukemia (CML) has evolved significantly since the introduction of imatinib. The European LeukemiaNet (ELN) recommendations serve as a guide for diagnosis, treatment, and monitorization of CML, but availability and accessibility of diagnostic tools and medications affect their applicability. Areas covered This article provides an overview of the current clinical management of CML in Turkey with reference to the key outputs of the online expert meeting held in November 2020. The applicability of the ELN 2020 recommendations for treating CML in clinical practice was also discussed. Expert opinion Imatinib is the only reimbursed and the most preferred first-line treatment in CML restricting the upfront use of second-generation tyrosine kinase inhibitors (TKIs), thereby limiting the applicability of treatment-free remission approach in Turkey. The ELN recommendations about using the EUTOS Long-Term Survival (ELTS) score for risk assessment and focusing on patient reported outcomes and quality of life can be enhanced with educational activities. The widespread availability of standardized technical infrastructure for diagnosing and monitoring CML will contribute to better disease management. Establishing a sustainable national database for CML is valuable for observing patient characteristics and disease outcomes as well as the impact of treatment patterns over time.en_US
dc.identifier.citationEşkazan, A.E., Ali, R., Alnıgeniş, E., Ayyıldız, O., Haznedaroğlu, İ., Kırkızlar, O. ve diğerleri. (2022). Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Review of Hematology, Early Access.en_US
dc.identifier.doi10.1080/17474086.2022.2044779
dc.identifier.issn1747-4086
dc.identifier.issn1747-4094
dc.identifier.pmid35184657
dc.identifier.scopus2-s2.0-85126047046
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://hdl.handle.net/11468/9591
dc.identifier.volumeEarly Accessen_US
dc.identifier.wosWOS:000764920100001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAyyıldız, Orhan
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.ispartofExpert Review of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic myeloid leukemiaen_US
dc.subjectCMLen_US
dc.subjectComorbiditiesen_US
dc.subjectRisk scoringen_US
dc.subjectTKIen_US
dc.subjectTyrosine kinase inhibitoren_US
dc.subjectTFRen_US
dc.subjectTreatment-free remissionen_US
dc.titlePatient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meetingen_US
dc.titlePatient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu